目的 探討血管內皮生長因子（VEGF）及受體Flt-1蛋白表達與卵巢惡性腫瘤臨床病理和預后的關系。 方法 2000年1月-2004年6月，以SABC免疫組織化學方法檢測48例卵巢惡性腫瘤組織中VEGF及其受體Flt-1蛋白的表達。 結果 VEGF和Flt-1蛋白表達與卵巢惡性腫瘤的病理學類型、分化級別及臨床分期無明顯相關性（P＞0.05）。有淋巴結轉移者VEGF和Flt-1蛋白的表達陽性率均明顯高于無淋巴結轉移者（P＜0.05）。 VEGF 和Flt-1共同表達者平均總生存期為27.88個月，明顯短于沒有共同表達者的36.04個月（95%CI 為33.42～38.65，P=0.022 3）。 結論 VEGF和Flt-1蛋白表達與卵巢惡性腫瘤的淋巴結轉移相關，可作為預測腫瘤轉移及預后的指標。
ObjectiveTo investigate the efficacy and safety of using tamoxifen sequential with the third generation aromatase inhibitors versus the third generation aromatase inhibitors or tamoxifen alone for postmenopausal hormone receptor-positive breast cancer patients.MethodsThe Cochrane Library (Issue 10, 2016), PubMed, EMbase, CNKI, and WanFang Data were searched to collect randomized controlled trials on using tamoxifen sequential with the third generation aromatase inhibitors versus the third generation aromatase inhibitors or tamoxifen alone for postmenopausal hormone receptor-positive breast cancer patients from inception to October, 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then meta-analysis was performed by using RevMan 5.3 software.ResultsA total of 9 studies involving 22 005 patients were included. The results of meta-analysis showed that the sequential therapy group was superior to the tamoxifen monotherapy group on overall survival (HR=0.71, 95%CI 0.52 to 0.98, P=0.04) and recurrence-free survival (HR=0.60, 95%CI 0.46 to 0.79, P=0.000 3). However, no significant difference was found in overall survival and disease free survival between the sequential therapy group and the aromatase inhibitors monotherapy group. As to adverse events, compared with the tamoxifen monotherapy group, the sequential therapy group could reduce the incidence of endometrial hyperplasia (OR=0.22, 95%CI 0.11 to 0.45, P<0.000 01), death (OR=0.74, 95%CI 0.66 to 0.84, P<0.000 01) and metastasis (OR=0.79, 95%CI 0.68 to 0.91, P=0.001); however, the incidence of bone fracture was higher in sequential therapy group compared with intamoxifen monotherapy group (OR=1.31, 95%CI 1.13 to 1.51, P=0.000 3).ConclusionThe sequential therapy using tamoxifen and the third generation of aromatase inhibitors is better than tamoxifen monotherapy for postmenopausal hormone receptor-positive breast cancer patients. However, there is no significant difference in survival benefit between the sequential therapy and aromatase inhibitors monotherapy.
Objective To approach the surgical therapeutic efficacy of local recurrence of rectal cancer. Methods Fifty-six patients with local recurrence of rectal cancer suffered from reoperation from January 2003 to January2011 in this hospital were collected. Chi-square test was performed to analyze the complete excision rates of reoperation for different recurrent time after radical resection and different surgical procedures after primary radical resection of rectalcancer. The method of log-rank test was used for survival analysis of the Miles and Dixon procedure. Results ①The opera-tion time and intraoperative bleeding of reoperation for local recurrence of rectal cancer were more than those of the primary radical resection of rectal cancer （P＜0.05）. ②The complete resection rate of the local recurrence of rectal cancer in 5 years after primary radical resection of rectal cancer was higher than that of the local recurrence of rectal cancer within 2 years after primary radical resection of rectal cancer， and the difference was statistically significant （P＜0.01）. ③The complete resection rate of the local recurrence of rectal cancer of the technique of Dixon in the primary radical resection of rectal cancer was higher than that of Miles， and the difference was statistically significant （P＜0.05）. ④The median survival time and 2-year survival rate and 5-year survival rate of the technique of Dixon in the reoperation were longer or higher than those of Miles， and the differences were statistically significant （P＜0.05）. Conclusions Surgical procedure and postoperative recurrence time after primary operation can both influence complete excision rate of reoperation for local recurrence of rectal cancer. And reoperation for local recurrence of rectal cancer can prolong the survival time.
Objective To evaluate the predictive performance of the geometric characteristics, centerline (CL) of pulmonary nodules for prognosis in patients with surgically treatment in the National Lung Screening Trial (NLST). MethodsCT images of 178 patients who underwent surgical treatment and were diagnosed with non-small cell lung cancer (NSCLC) in the low-dose CT (LDCT) cohort from the NLST image database were selected, including 99 males and 79 females, with a median age of 64 (59, 68) years. CT images were processed using commercial software Mimics 21.0 to record the volume, surface area, CL and the area perpendicular to the centerline of pulmonary nodules. Receiver operating characteristic (ROC) curve was used to compare the predictive performance of LD, AD and CL on prognosis. Univariate Cox regression was used to explore the influencing factors for postoperative disease-free survival (DFS) and overall survival (OS), and meaningful independent variables were included in the multivariate Cox regression to construct the prediction model. ResultsThe area under the curve (AUC) of CL for postoperative recurrence and death were 0.650 and 0.719, better than LD (0.596, 0.623) and AD (0.600, 0.631). Multivariate Cox proportional risk regression analysis showed that pulmonary nodule volume (P=0.010), the maximum area perpendicular to the centerline (MApc) (P=0.028) and lymph node metastasis (P<0.001) were independent risk factors for DFS. Meanwhile, age (P=0.010), CL (P=0.043), lymph node metastasis (P<0.001), MApc (P=0.022) and the average area perpendicular to the centerline (AApc) (P=0.016) were independently associated with OS. ConclusionFor the postoperative outcomes of NSCLC patients in the LDCT cohort of the NLST, the CL of the pulmonary nodule prediction performance for prognosis is superior to the LD and AD, CL can effectively predict the risk stratification and prognosis of lung cancer, and spheroid tumors have a better prognosis.
Survival prognosis in patients with terminal cancer plays an important role in clinical decision-making, policy formulation, and end-stage patient with relatives. To date, foreign researchers have developed multiple survival prediction models based on patient clinical performance, biomarkers and other indicators, along with a large number of studies which have been externally verified, including Palliative Performance Scale (PPS), Palliative Prognostic Score (PaP), Delirium-Palliative Prognostic Score (D-PaP), and Palliative Prognostic Index (PPI), etc. China's research on this topic remains in the primary stage. Therefore, this article reviews the prognostic factors of terminal cancer and survival prediction models as well as applications, in order to provide references for the subsequent construction of survival prediction models for patients with terminal cancer in line with Chinese characteristics.
ObjectiveTo detect level of circulating tumor cells (CTCs) in peripheral venous blood of fasting patients with gastric cancer (GC) and to analyze relationships between CTCs and clinicopathologic features and prognosis of patients with GC.MethodsOne hundred patients with GC were selected (GC group), who underwent the surgery and confirmed by the histopathology in the 940 Hospital of Joint Service of PLA, from August 2015 to December 2016. Thirty-eight patients with gastric benign lesions who were treated in this hospital at the same time were selected as the control group. The 7 mL peripheral venous blood of the elbow in the morning was taken from the fasting patients and the CTCs were detected by the immunomagnetic microparticle negative enrichment combined with immunofluorescence in situ hybridization within 24 h. The positive rate of CTCs was calculated and its relationships with the clinicopathologic features (tumor location, tumor invasion depth, degree of differentiation, TNM stage, lymph node metastasis, and vascular tumor thrombus) and the progression-free survival of the patients with GC were analyzed.ResultsThe positive rate of peripheral venous blood CTCs in the GC group was 89.0% (89/100), which was higher than that in the control group (10.5%, 4/38), and the difference was statistically significant (P<0.001). The levels of CTCs in the patients with GC were significantly correlated with the tumor invasion depth (P=0.017), lymph node metastasis (P=0.038), and TNM stage (P=0.016), which were not associated with the age, gender, tumor location, degree of differentiation, and vascular tumor thrombus (P>0.050). The predictive value of CTCs for the diagnosis of GC was significantly superior to that of the tumor markers CEA, CA19-9, or CA125. The progression-free survival of patients with low CTCs expression was significantly longer than that in the patients with high CTCs expression (χ2=5.172, P=0.023).ConclusionsDetecting CTCs of patients with GC by immunomagnetic particle negative enrichment combined with immunofluorescence in situ hybridization has a high sensitivity. And it can improve early diagnosis of patients with GC. Preoperative CTCs detection has a certain value in guiding staging of GC and predicting prognosis of patients with GC.
Objective To use a meta-analysis method to establish quantitatively the association between the HER-2/neu gene amplification/enhanced protein expression status and the 5-year post-operative survival rate or median survival time in women with epithelial ovarian carcinoma. Methods We searched and screened Chinese and English literature published since 1989 to collect all retrospective cohort studies on the prognostic significance of HER-2/neu status in this population. The survival data were analyzed using Ludwig’s centered signed rank and the DerSimonian-Laird method. Results In total, 25 studies involving 3 251 patients were included. HER-2/neu was positive in 27.1% (95%CI 0 to 54.8%) of patients, which was not related to the pathological stage, type or grade of epithelial ovarian carcinoma. In HER-2/neu positive cases, the median survival time was shortened by 0.65 years, and the 5-year survival rate was lowered. The hazard ratio (HR) for mortality was 1.22 (95%C 1.09 to 1.36). By subgroup analysis, HER-2/neu protein expression was found to be most significant in prognostic assessment. Patients with a b positive value of HER-2/neu had an increased HR for the 5-year survival; and platinum-based chemotherapy was demonstrated to be less effective in HER-2/neu positive ovarian carcinoma. Conclusion In gynecological oncology, it is reasonable to measure HER-2/neu as a routine pathological marker to predict a patient’s prognosis and to determine the most appropriate adjuvant chemotherapy regimen.
目的 探討結腸癌患者術后3年生存情況的影響因素。方法 回顧2006年1月至2007年12月期間筆者所在科室收治的確診為結腸癌且隨訪資料完整的169例患者臨床資料，從術前CEA水平、腫瘤病理分型、分化程度和體質指數（BMI）方面分析影響結腸癌預后的因素。結果 術前CEA水平、腫瘤分化程度及BMI對術后3年生存期的差異有統計學意義（P＜0.05），術前CEA水平對術后3年生存率的差異均有統計學意義（P＜0.05）；術前CEA水平、病理分型、分化程度對術后發生轉移的差異有統計學意義（P＜0.05）。結論 術前CEA水平是結腸癌預后的高危因素。
ObjectiveThis study aimed to identify independent risk factors for head and neck squamous cell carcinoma (HNSCC) based on the surveillance, epidemiology, and end results (SEER) database and to develop a nomogram model for predicting patient survival outcomes. MethodsPatients diagnosed with HNSCC from 1975 to 2021 were selected from the SEER database. After applying inclusion and exclusion criteria, 2 271 patients were included and randomly divided into a training cohort and a validation cohort in a 7∶3 ratio. Independent prognostic factors were identified using LASSO regression, Cox regression analysis, and the Akaike information criterion (AIC). A nomogram model was constructed, and its discrimination and calibration were assessed using the concordance index (C-index), time-dependent area under the curve (time-dependent AUC), and calibration curves. The nomogram model was compared with the American Joint Committee on Cancer (AJCC) staging system using decision curve analysis (DCA), net reclassification index (NRI), and integrated discrimination improvement (IDI) to evaluate clinical utility and risk stratification performance. ResultsFive independent prognostic factors (age, marital status, N stage, tumor stage, and radiotherapy) were selected to build the nomogram model for HNSCC. The C-index values of the model were 0.731 4 (95%CI 0.714 5 to 0.748 5) in the training cohort and 0.735 1 (95%CI 0.709 1 to 0.761 0) in the validation cohort. The time-dependent AUC values were all above 0.7, indicating good discriminatory ability. Moreover, decision curve analysis showed that the nomogram model provided higher clinical net benefits at different threshold probabilities and performed better than the AJCC staging system in identifying high-risk patients. ConclusionThis study develops a nomogram model based on the SEER database to predict survival outcomes in patients with HNSCC. The model demonstrates high discrimination and clinical utility, offering a personalized prognostic tool for clinicians.
ObjectiveTo explore the prognostic value of modified Glasgow Prognostic Score (mGPS) in lung cancer patients.MethodsThe clinical data and follow-up information of patients with lung cancer diagnosed for the first time in West China Hospital of Sichuan University from August 2008 to May 2013 were retrospectively analyzed. Overall survival (OS) of patients with different mGPS were compared by Kaplan-Meier test and log-rank test. Univariate and multivariate Cox proportional hazard analysis were performed, and hazard ratio (HR) and 95% confidence interval (CI) were counted to evaluate the predictive value of different prognostic factors in patients with lung cancer.ResultsA total of 289 patients were included. According to the mGPS score, 127 patients had 0 point, 90 patients had 1 point, and 72 patients had 2 points. The OS of lung cancer patients with mGPS=0 was better than that of patients with mGPS=1 and mGPS=2 (P<0.001). Cox proportional hazards of univariate analysis revealed that age< 65 (P=0.022), stage for Ⅰand Ⅱ (P<0.001), surgery (P<0.001), chemotherapy (P=0.018), and mGPS=0 (1 vs. 0, P=0.008; 2 vs. 0, P<0.001) were the protective factors for lung cancer patients (P<0.05). Multiple-factor analysis showed that age [HR=0.680, 95%CI (0.508, 0.911), P=0.010], stage [HR=0.580, 95%CI (0.359, 0.939), P=0.027], operation [HR=0.254, 95%CI (0.140, 0.459), P<0.001], chemotherapy [HR=0.624, 95%CI (0.435, 0.893), P=0.010], mGPS (1 vs. 0) [HR=1.548, 95%CI (1.101, 2.176), P=0.012] and mGPS (2 vs. 0) [HR=1.425, 95%CI (1.003, 2.024), P=0.048] were independent predictors of OS in patients with lung cancer.ConclusionmGPS could be considered as an independent prognostic factor in lung cancer.